LUND, Sweden, Jan. 7, 2021 /PRNewswire/ -- Immunovia
AB, ("Immunovia") a diagnostic company that develops highly
accurate blood tests for the early detection of cancer and
autoimmune diseases, today announced results from a study in their
development pipeline, published in the peer-reviewed Journal of
Proteome Research. These are the first proteomic data allowing
a differential analysis of four different inflammatory rheumatic
diseases (IRDs).
Early and correct diagnosis of inflammatory rheumatic diseases
is presently a clinical challenge due to the variety of symptoms.
The aim of the study was to achieve protein expression profiles
distinguishing four systemic IRDs, that if left untreated, can lead
to severe and sometimes permanent disability, increased morbidity,
and premature mortality. A total of 316 serum samples collected
from patients with Systemic Lupus Erythematosus (SLE), ANCA
associated systemic vasculitis (SV), Rheumatoid Arthritis (RA) and
Sjögren's Syndrome (SS), and healthy controls were analysed, using
Immunovia's recombinant antibody microarray (IMMray™). Differential
protein expression profiling was examined using Wilcoxon signed
rank test and condensed biomarker panels could be identified
reflecting each disease, using advanced bioinformatics and
state-of-the art classification algorithms.
Lead author, Mattias
Ohlsson, Professor Computational Biology and
Biological Physics at Lund
University comments: "In this study we were able to classify the
included individual IRDs with high accuracy, as demonstrated by ROC
Area Under the Curve (ROC AUC) values ranging between 0.96 and
0.80. The groups of IRDs could be separated from healthy controls
at a ROC AUC value of 0.94. We believe this supports the rationale
of using IMMray™ to reflect the biological complexity of autoimmune
diseases."
Patrik Dahlen, CEO,
Immunovia added: "Autoimmune diseases today pose a
global health issue, affecting millions of people around the globe
and there is an urgent need for refined clinical tools for early
and differential diagnosis. These results suggest that the use of a
multiplexed approach such as IMMray™ is highly suitable for
decoding multifactorial diseases like autoimmune diseases. Early
diagnosis in turn will help to prevent severe organ and tissue
related damages. We will incorporate these signatures and further
evaluate them in our discovery program for autoimmune
diseases."
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Patrik Dahlen,
CEO, Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/proteomic-data-derived-from-immunovia-s-immray-platform-allows-differential-diagnosis-of-difficult-t,c3264922
The following files are available for download:
https://mb.cision.com/Main/13121/3264922/1356800.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/proteomic-data-derived-from-immunovias-immray-platform-allows-differential-diagnosis-of-difficult-to-distinguish-autoimmune-diseases-301202722.html
SOURCE Immunovia AB